Newtyn Management, LLC Black Diamond Therapeutics, Inc. Transaction History
Newtyn Management, LLC
- $458 Million
- Q2 2024
A detailed history of Newtyn Management, LLC transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Newtyn Management, LLC holds 95,000 shares of BDTX stock, worth $513,000. This represents 0.1% of its overall portfolio holdings.
Number of Shares
95,000
Previous 125,000
24.0%
Holding current value
$513,000
Previous $633,000
30.17%
% of portfolio
0.1%
Previous 0.14%
Shares
9 transactions
Others Institutions Holding BDTX
# of Institutions
99Shares Held
47.3MCall Options Held
108KPut Options Held
24.8K-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.7MShares$57.6 Million0.03% of portfolio
-
Bellevue Group Ag Kuesnacht, V88.52MShares$46 Million0.66% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$24 Million1.96% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$17.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.13MShares$11.5 Million0.0% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $196M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...